IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Bokf Na

Bokf Na trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,425 shares of the company’s stock after selling 134 shares during the period. Bokf Na’s holdings in IDEXX Laboratories were worth $1,669,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Avantax Advisory Services Inc. raised its stake in IDEXX Laboratories by 21.1% in the 4th quarter. Avantax Advisory Services Inc. now owns 632 shares of the company’s stock valued at $351,000 after purchasing an additional 110 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in shares of IDEXX Laboratories by 14.5% in the fourth quarter. Quadrant Capital Group LLC now owns 662 shares of the company’s stock worth $367,000 after buying an additional 84 shares in the last quarter. Haverford Trust Co acquired a new position in IDEXX Laboratories during the fourth quarter worth about $213,000. Panagora Asset Management Inc. grew its stake in IDEXX Laboratories by 2.8% during the 4th quarter. Panagora Asset Management Inc. now owns 1,523 shares of the company’s stock valued at $845,000 after acquiring an additional 41 shares in the last quarter. Finally, Navellier & Associates Inc. acquired a new stake in IDEXX Laboratories in the 4th quarter valued at about $207,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on IDXX. BTIG Research initiated coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target for the company. Stifel Nicolaus dropped their target price on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. Piper Sandler reduced their price target on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Finally, StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $582.25.

IDEXX Laboratories Stock Up 0.7 %

Shares of NASDAQ:IDXX opened at $500.55 on Friday. The company has a market capitalization of $41.20 billion, a price-to-earnings ratio of 48.46, a PEG ratio of 4.17 and a beta of 1.33. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The business has a 50-day moving average price of $481.18 and a 200 day moving average price of $501.22. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing the consensus estimate of $2.88 by ($0.44). The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.01 billion. IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The company’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same period last year, the business earned $2.67 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.45 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.